Last reviewed · How we verify
NCT06989723
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Phase 4 trial testing Pioglitazone 15 MG [Actos] in Type 2 Diabetes in 120 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Pioglitazone 15 MG [Actos] — full drug profile →
- Empagliflozin 10 MG [Jardiance] — full drug profile →
- Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Fatty Liver — all drugs for Fatty Liver →
Sponsor
Seoul National University Bundang Hospital
Who can join
20 and older, any sex, with Type 2 Diabetes or Fatty Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06989723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06989723 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06989723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing